Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA just greenlit satralizumab (Enspryng) for thyroid eye disease (TED) — making it the first treatment patients can self-administer at home via subcutaneous injection. Approval was backed by the SatraGO-2 trial, which showed significantly better proptosis and diplopia responses versus placebo. This adds to a rapidly growing toolkit for a condition that, until recently, had very few targeted options.
The FDA approved satralizumab-mwge (Enspryng, Genentech/Roche) on October 15 for adults with thyroid eye disease (TED), marking a notable milestone: it's the first subcutaneous TED therapy patients or caregivers can administer at home after clinician training. The drug works by blocking interleukin-6 (IL-6) receptors, dampening the inflammatory cascade that drives TED. It was previously approved in 2020 for neuromyelitis optica spectrum disorder.
The approval rests on the phase 3 SatraGO program. While SatraGO-1 missed its primary endpoint at week 24, SatraGO-2 delivered compelling results in the active TED population, showing meaningful improvements in both eye protrusion and double vision compared to placebo.
By the Numbers:
Why it matters: TED is rare but can be vision-threatening and significantly impacts quality of life. The at-home administration option is a meaningful convenience upgrade over IV infusions, and the expanding roster of approved biologics gives clinicians more tools — though experts stress that head-to-head trials are still needed to guide treatment choices.
